Cancer
Conditions
Sponsors
Hoffmann La Roche
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Metastatic or locally advanced unresectable, histologically documented triple-negative breast cancer (TNBC) (absence of HER2-over-expression, ER, and PgR expression by local assessment) HER2-low-status Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 If metastatic disease (Stage IV), measurable disease outside of the bone No prior systemic therapy for metastatic or locally advanced unresectable TNBC Tumor PD-L1 expression as documented through central testing of a representative tumor tissue specimen Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Adequate hematologic and end-organ function Negative HIV test at screening, with the following exception: individuals with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count = 200/uL, and have an undetectable viral load Negative hepatitis B surface antigen (HBsAg) test at screening Positive hepatitis B surface antibody (HBsAb) test at screening, or a negative HBsAb at screening accompanied by either of the following: negative hepatitis B core antibody (HBcAb); positive HBcAb test followed by quantitative hepatitis B virus (HBV) DNA < 500 IU/mL Negative hepatitis C virus (HCV) antibody test at screening, or a positive HCV antibody test followed by a negative HCV RNA test at screening Adequate cardiovascular function
Exclusion criteria
Exclusion criteria: Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 4 months after the final dose of tobemstomig or pembrolizumab, and 6 months after the final dose of nab-paclitaxel Poor venous access History of malignancy within 5 years prior to consent, except for the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate >90%), such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases History of leptomeningeal disease Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) Hypercalcemia or hypercalcemia that is symptomatic Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis (granulomatosis with polyangiitis), Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted Active tuberculosis (TB) Significant cardiovascular/cerebrovascular disease within 3 months prior to consent History or presence of an abnormal ECG that is deemed clinically significant History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (sym
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR);Duration of Response (DOR;Overall Survival (OS);PFS rate at 12 months;OS rate at 12 months;Serum Concentration of Tobemstomig;Incidence of Anti-Drug Antibodies (ADAs) to Tobemstomig | — |
Countries
Kenya
Contacts
Public ContactArpna Patel
Country Operational Lead
Outcome results
None listed